CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.
Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .
Rezultaty
Generate VLPs for two TBV candidates and assess immunogenicity and TB activity
6.4 Preclinical studies completed for adjuvantPreclinical studies completed for adjuvant
7.5 Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteersReport on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers
1.5 Generation of 8 transgenic P berghei parasites expressing novel P falciparum antigensCreation of 8 transgenic P. berghei parasites expressing novel P. falciparum sporozoite antigens
10.2 Establish relevant committees including PSC, PMMC, ISACReport on the establishment of relevant committees including the Project Steering Committee and a Project Management and Monitoring Committee, and ISAC
2.1 Liver-stage antigens identified from HLA molecules of parasitized hepatocytesReport on the nature of liver-stage antigens identified by sequencing of eluted peptides from the HLA molecules of parasitized hepatocytes
5.2 Adequate process for lead novel VLPs for initial GMP productionAdequate process for lead novel VLPs for initial (Phase I trial scale) GMP production
2.3 Rank ordering of the protective efficacy of new liver-stage antigen candidatesRank ordering of the protective efficacy of new liverstage antigen candidates assessed in in vivo murine models using transgenic parasite challenge
5.1 generation of five new VLPs with SnoopCatcher and SpyCatcherReport on generation of five new VLPs with SnoopCatcher and SpyCatcher and on the relative robustness of each platform for displaying multiple antigens
1.4 Generation of 8 new vectored vaccine candidatesGeneration of 8 new vectored vaccine candidates expressing the 8 elected antigens of deliverable 1.1.
1.3 Generation of lead bivalent sporozoite VLP suitable for progression to GMPGeneration of lead bivalent sporozoite VLP suitable for progression to GMP biomanufacture
4.1 Identification of new novel candidates from natural blockers and proteomic screenIdentification of new novel candidates from natural blockers and proteomic screen
4.5 Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufactureAssess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture
3.4 Efficacy of new candidate blood-stage antigensReport on efficacy of new candidate bloodstage antigens
3.1 Preferred VLP for generation of bi-valent blood-stage immunogenReport on preferred VLP for generation of a bi-valent blood-stage immunogen
3.2 Immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLPReport on the immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP
5.3 Comparison of immunogenicity of lead VLPs and evidence of non-interferenceComparison of immunogenicity of the VLPs generated with identification of the lead VLPs and evidence of non-interference between lead sporozoite-, blood-stage and transmission-stage VLPs
7.7 Report on safety and immunogenicity of R21b in matrix M adjuvantReport on safety and immunogenicity of R21b in matrix M adjuvant
2.4 Utility of new prime-target immunisation approaches in liver-stage protective immunity in miceReport of the utility of new primetarget immunisation approaches in generating durable liverstage protective immunity in mice
1.6 Efficacy data on new antigens allowing rank orderingEfficacy data on new sporozoite antigens allowing rank ordering of protective efficacy of lead antigens
8.4 Report on safety and immunogenicity of blood-stage VLP/vaccineReport on safety and immunogenicity of bloodstage VLPvaccine in clinical trial
10.8 List of publicationsList of publications arising from project including any at manuscript preparation stage as some data may not be published until after the end date of the project
4.2 Validation of selected novel candidate and comparison with leading antigensValidation of selected novel candidate and comparison with leading antigens
7.6 Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteersReport on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers
3.3 Structural studies of PfRH5 pathway componentsReport on structural studies of PfRH5 pathway components
9.5 TB activity of TBV candidatesTransmission Blocking activity of TBV candidates
5.4 Optimised process for biomanufacture of lead novel VLPs for GMP productionOptimised process for biomanufacture of lead novel VLPs for high yield larger scale GMP production
2.2 Ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopesReport on the ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes inserted into P. falciparum liver-stage antigens by CRISPR/Cas9 technology
4.4 Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPsGenerate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs
8.5 Report on immuno-efficacy of blood-stage VLP/vaccineReport on immunoefficacy of bloodstage VLPvaccine in clinical trial
1.2 Definition of 8 selected new candidate sporozoite antigensDefinition of 8 selected new candidate sporozoite antigens based on invasion analysis, proteomics and immunoepidemiology
9.4 Safety and Immunogenicity of TBV candidatesSafety and Immunogenicity of TBV candidates
7.8 Report on efficacy against sporozoite challenge of vectored prime-target immunisation combined with R21b in healthy volunteersReport on efficacy against sporozoite challenge of vectored primetarget immunisation combined with R21b in healthy volunteers
5.5 feasibility of enhancing the durability of protective immune responses using VLPs in microcapsulesReport on the feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules
Successful creation of project website
Publikacje
Autorzy:
Roos M. de Jong, Susheel K. Singh, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Will J. R. Stone, Emily Locke, Jordan Plieskatt, Michael Theisen, Teun Bousema, Matthijs M. Jore
Opublikowane w:
Frontiers in Immunology, 2022, ISSN 1664-3224
Wydawca:
Frontiers Media SA
DOI:
10.3389/fimmu.2022.909060
Autorzy:
Surendra Kumar Kolli, Ahmed M. Salman, Jai Ramesar, Severine Chevalley-Maurel, Hans Kroeze, Fiona G. A. Geurten, Shinya Miyazaki, Ekta Mukhopadhyay, Catherin Marin-Mogollon, Blandine Franke-Fayard, Adrian V. S. Hill, Chris J. Janse
Opublikowane w:
PLOS ONE, Numer 16/7, 2021, Strona(/y) e0254498, ISSN 1932-6203
Wydawca:
Public Library of Science
DOI:
10.1371/journal.pone.0254498
Autorzy:
Susheel K. Singh1,2, Jordan Plieskatt3, Bishwanath K. Chourasia1,2, Vandana Singh1,2, Karin Lövgren Bengtsson4, Jenny M. Reimer 4, Renate C. van Daalen5, Karina Teelen5, Marga van de Vegte-Bolmer5, Geert-Jan van Gemert5, Matthijs M. Jore 5,6✉ and Michael Theisen
Opublikowane w:
NPJ Vaccines, 2021, ISSN 2059-0105
Wydawca:
Springer Nature
DOI:
10.1038/s41541-021-00383-8
Autorzy:
Ko KT, Lennartz F, Mekhaiel D, Guloglu B, Marini A, Deuker DJ, Long CA, Jore MM, Miura K, Biswas S, Higgins MK
Opublikowane w:
Nature Communications, 2022, ISSN 2041-1723
Wydawca:
Nature Publishing Group
DOI:
10.1038/s41467-022-33379-6
Autorzy:
Susheel K. Singh, Jordan Plieskatt, Bishwanath K. Chourasia, Amanda Fabra-García, Asier Garcia-Senosiain, Vandana Singh, Karin Lövgren Bengtsson, Jenny M. Reimer, Robert Sauerwein, Matthijs M. Jore, Michael Theisen
Opublikowane w:
Frontiers in Immunology, Numer 11, 2021, ISSN 1664-3224
Wydawca:
Frontiers in Immunology
DOI:
10.3389/fimmu.2020.606266
Autorzy:
Meerstein-Kessel L, Venhuizen J, Garza D, Proellochs NI, Vos EJ, Obiero JM, et al.
Opublikowane w:
PLoS Comput. Biol., 2021, ISSN 1553-7358
Wydawca:
PLOS
DOI:
10.1371/journal.pcbi.1008067
Autorzy:
Kirsten Dundas, Melanie J. Shears, Yi Sun, Christine S. Hopp, Cecile Crosnier, Tom Metcalf, Gareth Girling, Photini Sinnis, Oliver Billker, Gavin J. Wright
Opublikowane w:
Proceedings of the National Academy of Sciences, Numer 115/17, 2018, Strona(/y) 4477-4482, ISSN 0027-8424
Wydawca:
National Academy of Sciences
DOI:
10.1073/pnas.1719660115
Autorzy:
Daniel G.W. Alanine, Doris Quinkert, Rasika Kumarasingha, Shahid Mehmood, Francesca R. Donnellan, Nana K. Minkah, Bernadeta Dadonaite, Ababacar Diouf, Francis Galaway, Sarah E. Silk, Abhishek Jamwal, Jennifer M. Marshall, Kazutoyo Miura, Lander Foquet, Sean C. Elias, Geneviève M. Labbé, Alexander D. Douglas, Jing Jin, Ruth O. Payne, Joseph J. Illingworth, David J. Pattinson, David Pulido, Barnab
Opublikowane w:
Cell, Numer 178/1, 2019, Strona(/y) 216-228.e21, ISSN 0092-8674
Wydawca:
Cell Press
DOI:
10.1016/j.cell.2019.05.025
Autorzy:
Arianna Marini, Yu Zhou, Yuanyuan Li, Iona J. Taylor, Darren B. Leneghan, Jing Jin, Marija Zaric, David Mekhaiel, Carole A. Long, Kazutoyo Miura, Sumi Biswas
Opublikowane w:
Frontiers in Immunology, Numer 10, 2019, Strona(/y) Artiicle 2931, ISSN 1664-3224
Wydawca:
Unknown
DOI:
10.3389/fimmu.2019.02931
Autorzy:
Susheel K. Singh, Susan Thrane, Bishwanath K. Chourasia, Karina Teelen, Wouter Graumans, Rianne Stoter, Geert-Jan van Gemert, Marga G. van de Vegte-Bolmer, Morten A. Nielsen, Ali Salanti, Adam F. Sander, Robert W. Sauerwein, Matthijs M. Jore, Michael Theisen
Opublikowane w:
Frontiers in Immunology, Numer 10, 2019, Strona(/y) Article 1256, ISSN 1664-3224
Wydawca:
Unknown
DOI:
10.3389/fimmu.2019.01256
Autorzy:
Paulo Bettencourt
Opublikowane w:
Frontiers in Immunology, Numer 11, 2020, Strona(/y) Article 190, ISSN 1664-3224
Wydawca:
Unknown
DOI:
10.3389/fimmu.2020.00190
Autorzy:
Roos M. Jong, Surafel K. Tebeje, Lisette Meerstein‐Kessel, Fitsum G. Tadesse, Matthijs M. Jore, Will Stone, Teun Bousema
Opublikowane w:
Immunological Reviews, Numer 293/1, 2019, Strona(/y) 190-215, ISSN 0105-2896
Wydawca:
Blackwell Publishing Inc.
DOI:
10.1111/imr.12828
Autorzy:
Joseph J. Illingworth, Daniel G. Alanine, Rebecca Brown, Jennifer M. Marshall, Helen E. Bartlett, Sarah E. Silk, Geneviève M. Labbé, Doris Quinkert, Jee Sun Cho, Jason P. Wendler, David J. Pattinson, Lea Barfod, Alexander D. Douglas, Michael W. Shea, Katherine E. Wright, Simone C. de Cassan, Matthew K. Higgins, Simon J. Draper
Opublikowane w:
Frontiers in Immunology, Numer 10, 2019, Strona(/y) Article 1254, ISSN 1664-3224
Wydawca:
Unknown
DOI:
10.3389/fimmu.2019.01254
Autorzy:
Shinya Miyazaki, Annie S. P. Yang, Fiona J. A. Geurten, Catherin Marin-Mogollon, Yukiko Miyazaki, Takashi Imai, Surendra Kumar Kolli, Jai Ramesar, Severine Chevalley-Maurel, Ahmed M. Salman, Geert-Jan A. van Gemert, Youri M. van Waardenburg, Blandine Franke-Fayard, Adrian V. S. Hill, Robert W. Sauerwein, Chris J. Janse, Shahid M. Khan
Opublikowane w:
Frontiers in Cellular and Infection Microbiology, Numer 10, 2020, ISSN 2235-2988
Wydawca:
Frontiers Media S. A.
DOI:
10.3389/fcimb.2020.00270
Autorzy:
Boltryk SD, Passecker A, Alder A, Carrington E, van de Vegte-Bolmer M, van Gemert G-J, et al
Opublikowane w:
Nature Communications, 2021, ISSN 2041-1723
Wydawca:
Nature Publishing Group
DOI:
10.1038/s41467-021-24954-4
Autorzy:
Rameswara Reddy Segireddy, Kirsten Dundas, Julia Knoeckel, Francis Galaway, Laura Wood, Gavin J Wright, View ORCID ProfileAlexander D Douglas
Opublikowane w:
TBD, Numer TBD, 2020, Strona(/y) TBD
Wydawca:
TBD
DOI:
10.1101/2020.02.02.929190
Prawa własności intelektualnej
Numer wniosku/publikacji:
20
20058906
Data:
2020-03-30
Wnioskodawca/wnioskodawcy:
STATENS SERUM INSTITUT
Numer wniosku/publikacji:
20
20058906
Data:
2020-03-30
Wnioskodawca/wnioskodawcy:
STATENS SERUM INSTITUT
Numer wniosku/publikacji:
20
728129
Data:
2020-05-11
Wnioskodawca/wnioskodawcy:
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Numer wniosku/publikacji:
20
728129
Data:
2020-05-11
Wyszukiwanie danych OpenAIRE...
Podczas wyszukiwania danych OpenAIRE wystąpił błąd
Brak wyników